Literature DB >> 19418409

Presumed cryptogenic liver disease in Germany: High prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology.

S Heringlake1, A Schütte, P Flemming, W Schmiegel, M P Manns, H L Tillmann.   

Abstract

UNLABELLED: Aim was to investigate possible underlying causes of presumed cryptogenic liver disease.
METHODS: A cohort of 126 consecutive patients with presumed cryptogenic hepatitis referred to a university hospital were reanalysed with respect to their clinical, laboratory and histological data.
RESULTS: In 19 patients there was evidence for an exogenous-toxic liver damage. Diagnosis of non-alcoholic steatohepatitis could be established in 22 patients. Viral origin was excluded in all patients by serological and PCR-based assays for the known hepatitis viruses and the viruses GBV-C and SENV. Furthermore, transmission studies in non-human primates using acute phase plasma of patients with severe cryptogenic hepatitis revealed no episode of transmissible hepatitis, that could give a hint to so far unknown viruses as etiological agent. In all patients negative autoantibodies were recorded. Nevertheless, in 43 patients the diagnosis of definite or probable seronegative autoimmune hepatitis (AIH) could be assumed by the application of the International Autoimmune Hepatitis (IAH)-Score. Only 42 patients still remained with cryptogenic liver disease (CLD). Compared to patients with seronegative AIH patients with CLD were significantly older, had a longer duration of their disease, lower values of transaminases, more frequently a cholestatic liver enzyme pattern, a lower grade of inflammation in the liver and no response to immunosuppressive therapy.
CONCLUSION: Only one third of patients with initially presumed cryptogenic liver disease remained cryptogenic, while another third of patients could be identified as seronegative autoimmune hepatitis by the IAH-Score with obvious benefit from immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19418409     DOI: 10.1055/s-0028-1109146

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  17 in total

Review 1.  Cryptogenic cirrhosis: what are we missing?

Authors:  Stephen Caldwell
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 2.  Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2017-07-14       Impact factor: 3.199

Review 3.  Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination.

Authors:  Albert J Czaja
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

Review 4.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

Review 5.  Cryptogenic chronic hepatitis and its changing guise in adults.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

Review 6.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

7.  Keratin 8 variants are associated with cryptogenic hepatitis.

Authors:  Mario Zierden; Arndt-Hendrik Penner; Manuel Montesinos-Rongen; Maren Weferling; Uta Drebber; Judith Stift; Jochen W U Fries; Margarete Odenthal; Stephan Rosenkranz; Hans-Peter Dienes
Journal:  Virchows Arch       Date:  2012-03-15       Impact factor: 4.064

Review 8.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 9.  Persistent hypertransaminasemia in asymptomatic children: a stepwise approach.

Authors:  Pietro Vajro; Sergio Maddaluno; Claudio Veropalumbo
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

Review 10.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.